033270.KS
Strong BuyUnloved QualityAI neutralKorea United Pharm Inc. · Healthcare · South Korea · $206M
KRW 17,530 -1.1% · close 2 Oct · scored 6 Oct
Unloved Quality: Strong and cheap; the market has not turned yet.
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Korea United Pharm makes generic and incrementally improved drugs, largely for the Korean market, and screens cheaply with solid quality. Domestic generics face regular government price cuts and a crowded field, and there is no recent news on its pipeline or export growth.
ABOUT KOREA UNITED PHARM INC.
Read
Korea United Pharm Inc. is a specialty pharmaceutical company focused on the research, development, and manufacturing of generic and incrementally modified drugs (IMDs). The company's competitive moat lies in its proprietary formulation technologies, which allow it to develop high-margin IMDs with improved efficacy and reduced side effects. It operates as a niche market leader in South Korea while actively expanding its export portfolio to over 40 countries.
FINANCIAL SUMMARY (KRW)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 262.5B | 278.9B | 288.7B | 288.8B | 3.2% | 161.6B |
| EPS (KRW) | 3,058 | 3,298 | 2,209 | 2,614 | -5.1% | 2,617 |
| Shares | 14.7M | 14.6M | 14.7M | 14.4M | -1.8% | 15.9M |
| Debt | 30.3B | 40.3B | 15.6B | 14.0B | -22.6% | 23.7B |
| Equity | 337.9B | 378.7B | 406.2B | 454.6B | 10.4% | — |
| Op CF | 63.8B | 49.8B | 26.8B | 51.1B | -7.1% | 25.0B |
| Inv CF | -87.9B | -55.5B | 11.7B | -41.1B | — | — |
| Fin CF | -10.6B | 2.5B | -29.5B | -3.6B | — | — |
Calmer than 81% of stocks we rank over the past year (25% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 033270.KS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 033270.KS | Korea United Pharm Inc.(you) | $206M | 87 | Strong Buy |
| 005500.KS | Samjin Pharmaceuticals Co., Ltd. | $172M | 90 | Strong Buy |
| 008490.KS | Suheung Co., Ltd. | $163M | 82 | Strong Buy |
| 001630.KS | Chong Kun Dang Holdings Corp. | $132M | 86 | Strong Buy |
| 096760.KS | JW Holdings Corporation | $221M | 100 | Strong Buy |
| 023910.KQ | Daihan Pharmaceutical Co.,Ltd. | $114M | 90 | Strong Buy |
| 016580.KS | Whan In Pharm Co.,Ltd. | $137M | 94 | Strong Buy |
| 234080.KS | JW Lifescience Corporation | $126M | 94 | Strong Buy |
| 000640.KS | Dong-A Socio Holdings Co., Ltd. | $440M | 91 | Strong Buy |
| 243070.KQ | Huons Co., Ltd. | $162M | 73 | Buy |
Peer medians: ROE -0.3% · P/E 17.6x · Gross margin 43.0%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.